MedPath
FDA Approval

Daliresp

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
March 12, 2020
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Roflumilast(250 ug in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

AstraZeneca

230790719

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Daliresp

Product Details

NDC Product Code
0310-0088
Application Number
NDA022522
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
March 12, 2020
starch, cornInactive
Code: O8232NY3SJClass: IACT
POVIDONE, UNSPECIFIEDInactive
Code: FZ989GH94EClass: IACT
Code: 0P6C6ZOP5UClass: ACTIBQuantity: 250 ug in 1 1
lactose monohydrateInactive
Code: EWQ57Q8I5XClass: IACT
magnesium stearateInactive
Code: 70097M6I30Class: IACT

Daliresp

Product Details

NDC Product Code
0310-0095
Application Number
NDA022522
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
March 12, 2020
starch, cornInactive
Code: O8232NY3SJClass: IACT
Code: 0P6C6ZOP5UClass: ACTIBQuantity: 500 ug in 1 1
POVIDONE, UNSPECIFIEDInactive
Code: FZ989GH94EClass: IACT
lactose monohydrateInactive
Code: EWQ57Q8I5XClass: IACT
magnesium stearateInactive
Code: 70097M6I30Class: IACT
© Copyright 2025. All Rights Reserved by MedPath